Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 451

1.

Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas.

Verver D, Poirier-Colame V, Tomasic G, Cherif-Rebai K, Grunhagen DJ, Verhoef C, Suciu S, Robert C, Zitvogel L, Eggermont AMM.

Oncoimmunology. 2019 Sep 6;8(11):e1660121. doi: 10.1080/2162402X.2019.1660121. eCollection 2019.

PMID:
31646109
2.

A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice.

Lévesque S, Le Naour J, Pietrocola F, Paillet J, Kremer M, Castoldi F, Baracco EE, Wang Y, Vacchelli E, Stoll G, Jolly A, De La Grange P, Zitvogel L, Kroemer G, Pol JG.

Oncoimmunology. 2019 Sep 7;8(11):e1657375. doi: 10.1080/2162402X.2019.1657375. eCollection 2019.

3.

Trial watch: dendritic cell vaccination for cancer immunotherapy.

Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S, Zitvogel L, Kroemer G, Galluzzi L, Garg AD.

Oncoimmunology. 2019 Jul 18;8(11):e1638212. doi: 10.1080/2162402X.2019.1638212. eCollection 2019. Review.

PMID:
31646087
4.

Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade.

Kepp O, Zitvogel L, Kroemer G.

Oncoimmunology. 2019 Jul 22;8(10):e1637188. doi: 10.1080/2162402X.2019.1637188. eCollection 2019.

PMID:
31646079
5.

Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies.

Kepp O, Marabelle A, Zitvogel L, Kroemer G.

Nat Rev Clin Oncol. 2019 Oct 8. doi: 10.1038/s41571-019-0272-7. [Epub ahead of print] Review.

PMID:
31595049
6.

Leptin-Producing Oncolytic Virus Makes Tumor-Infiltrating T Cells Fit, Not Fat.

Kroemer G, Zitvogel L.

Immunity. 2019 Sep 17;51(3):423-425. doi: 10.1016/j.immuni.2019.08.010.

PMID:
31533054
7.

Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity.

Yang H, Xia L, Chen J, Zhang S, Martin V, Li Q, Lin S, Chen J, Calmette J, Lu M, Fu L, Yang J, Pan Z, Yu K, He J, Morand E, Schlecht-Louf G, Krzysiek R, Zitvogel L, Kang B, Zhang Z, Leader A, Zhou P, Lanfumey L, Shi M, Kroemer G, Ma Y.

Nat Med. 2019 Sep;25(9):1428-1441. doi: 10.1038/s41591-019-0566-4. Epub 2019 Sep 9.

PMID:
31501614
8.

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.

Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, Messaoudene M, Enot DP, Stoll G, Ugel S, Marigo I, Foong Ngiow S, Marabelle A, Prevost-Blondel A, Gaudreau PO, Gopalakrishnan V, Eggermont AM, Opolon P, Klein C, Madonna G, Ascierto PA, Sucker A, Schadendorf D, Smyth MJ, Soria JC, Kroemer G, Bronte V, Wargo J, Zitvogel L.

Cell Res. 2019 Oct;29(10):846-861. doi: 10.1038/s41422-019-0224-x. Epub 2019 Sep 3.

PMID:
31481761
9.

A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers.

Kepp O, Sauvat A, Leduc M, Forveille S, Liu P, Zhao L, Bezu L, Xie W, Zitvogel L, Kroemer G.

Oncoimmunology. 2019 Apr 26;8(8):1606665. doi: 10.1080/2162402X.2019.1606665. eCollection 2019. Review.

PMID:
31413915
10.

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).

Ascierto PA, Agarwala SS, Botti G, Budillon A, Davies MA, Dummer R, Ernstoff M, Ferrone S, Formenti S, Gajewski TF, Garbe C, Hamid O, Lo RS, Luke JJ, Michielin O, Palmieri G, Zitvogel L, Marincola FM, Masucci G, Caracò C, Thurin M, Puzanov I.

J Transl Med. 2019 Jul 22;17(1):234. doi: 10.1186/s12967-019-1979-z.

11.

The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?

Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B.

Ann Oncol. 2019 Jul 3. pii: mdz206. doi: 10.1093/annonc/mdz206. [Epub ahead of print]

PMID:
31268133
12.

Interferon-γ induces cancer cell ferroptosis.

Zitvogel L, Kroemer G.

Cell Res. 2019 Sep;29(9):692-693. doi: 10.1038/s41422-019-0186-z. No abstract available.

PMID:
31160718
13.

Tumor lysis with LTX-401 creates anticancer immunity.

Xie W, Mondragón L, Mauseth B, Wang Y, Pol J, Lévesque S, Zhou H, Yamazaki T, Eksteen JJ, Zitvogel L, Sveinbjørnsson B, Rekdal Ø, Kepp O, Kroemer G.

Oncoimmunology. 2019 Apr 13;8(7):1594555. doi: 10.1080/2162402X.2019.1594555. eCollection 2019.

PMID:
31143516
14.

Trial watch: dietary interventions for cancer therapy.

Lévesque S, Pol JG, Ferrere G, Galluzzi L, Zitvogel L, Kroemer G.

Oncoimmunology. 2019 Apr 3;8(7):1591878. doi: 10.1080/2162402X.2019.1591878. eCollection 2019. Review.

15.

Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer.

Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, Martin T, Xia L, Yang H, Li Q, Chen J, Durand S, Aprahamian F, Lefevre D, Broutin S, Paci A, Bongers A, Minard-Colin V, Tartour E, Zitvogel L, Apetoh L, Ma Y, Pittet MJ, Kepp O, Kroemer G.

Nat Commun. 2019 Apr 17;10(1):1883. doi: 10.1038/s41467-019-09838-y.

16.

Crizotinib-induced immunogenic cell death in non-small cell lung cancer.

Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, Martin T, Xia L, Yang H, Li Q, Chen J, Durand S, Aprahamian F, Lefevre D, Broutin S, Paci A, Bongers A, Minard-Colin V, Tartour E, Zitvogel L, Apetoh L, Ma Y, Pittet MJ, Kepp O, Kroemer G.

Nat Commun. 2019 Apr 2;10(1):1486. doi: 10.1038/s41467-019-09415-3. Erratum in: Nat Commun. 2019 Apr 17;10(1):1883.

17.

T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.

Messaoudene M, Mourikis TP, Michels J, Fu Y, Bonvalet M, Lacroix-Trikki M, Routy B, Fluckiger A, Rusakiewicz S, Roberti MP, Cotteret S, Flament C, Poirier-Colame V, Jacquelot N, Ghiringhelli F, Caignard A, Eggermont AMM, Kroemer G, Marabelle A, Arnedos M, Vicier C, Dogan S, Jaulin F, Sammut SJ, Cope W, Caldas C, Delaloge S, McGranahan N, André F, Zitvogel L.

Ann Oncol. 2019 Mar 29. pii: mdz112. doi: 10.1093/annonc/mdz112. [Epub ahead of print]

PMID:
30924846
18.

Failure of immunosurveillance accelerates aging.

Perez-Lanzon M, Zitvogel L, Kroemer G.

Oncoimmunology. 2019 Feb 9;8(4):e1575117. doi: 10.1080/2162402X.2019.1575117. eCollection 2019.

19.

Anticancer effects of anti-CD47 immunotherapy in vivo.

Iribarren K, Buque A, Mondragon L, Xie W, Lévesque S, Pol J, Zitvogel L, Kepp O, Kroemer G.

Oncoimmunology. 2018 Dec 11;8(3):1550619. doi: 10.1080/2162402X.2018.1550619. eCollection 2019.

PMID:
30723582
20.

Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy.

Castoldi F, Vacchelli E, Zitvogel L, Maiuri MC, Pietrocola F, Kroemer G.

Oncoimmunology. 2018 Oct 1;8(1):e1498285. doi: 10.1080/2162402X.2018.1498285. eCollection 2019.

21.

Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Smith M, García-Martínez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Oct 11;7(12):e1526250. doi: 10.1080/2162402X.2018.1526250. eCollection 2018. Review.

22.

Trial watch: Peptide-based vaccines in anticancer therapy.

Bezu L, Kepp O, Cerrato G, Pol J, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Sep 6;7(12):e1511506. doi: 10.1080/2162402X.2018.1511506. eCollection 2018. Review.

23.

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Pol JG, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Fahrner JE, Fend L, Bell JC, Mossman KL, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018. Review.

24.

CD16+NKG2Ahigh Natural Killer Cells Infiltrate Breast Cancer-Draining Lymph Nodes.

Frazao A, Messaoudene M, Nunez N, Dulphy N, Roussin F, Sedlik C, Zitvogel L, Piaggio E, Toubert A, Caignard A.

Cancer Immunol Res. 2019 Feb;7(2):208-218. doi: 10.1158/2326-6066.CIR-18-0085. Epub 2018 Dec 4.

PMID:
30514793
25.

Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers.

Jacquelot N, Duong CPM, Belz GT, Zitvogel L.

Front Immunol. 2018 Oct 29;9:2480. doi: 10.3389/fimmu.2018.02480. eCollection 2018. Review.

26.

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade.

Hirsch L, Zitvogel L, Eggermont A, Marabelle A.

Br J Cancer. 2019 Jan;120(1):3-5. doi: 10.1038/s41416-018-0294-4. Epub 2018 Nov 9.

27.

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.

De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, Fucà G, Hiscott J, Malmberg KJ, McGranahan N, Pietrantonio F, Rivoltini L, Sangaletti S, Tagliabue E, Tripodo C, Vernieri C, Zitvogel L, Pupa SM, Di Nicola M.

Cytokine Growth Factor Rev. 2018 Dec;44:1-10. doi: 10.1016/j.cytogfr.2018.10.005. Epub 2018 Oct 30.

PMID:
30393044
28.

Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals.

Zhou H, Mondragón L, Xie W, Mauseth B, Leduc M, Sauvat A, Gomes-da-Silva LC, Forveille S, Iribarren K, Souquere S, Bezu L, Liu P, Zhao L, Zitvogel L, Sveinbjørnsson B, Eksteen JJ, Rekdal Ø, Kepp O, Kroemer G.

Cell Death Dis. 2018 Oct 23;9(11):1086. doi: 10.1038/s41419-018-1127-3.

29.

The intimate relationship between gut microbiota and cancer immunotherapy.

Elkrief A, Derosa L, Zitvogel L, Kroemer G, Routy B.

Gut Microbes. 2019;10(3):424-428. doi: 10.1080/19490976.2018.1527167. Epub 2018 Oct 19.

30.

Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts.

Stoll G, Pol J, Soumelis V, Zitvogel L, Kroemer G.

Oncoimmunology. 2018 Aug 6;7(10):e1484980. doi: 10.1080/2162402X.2018.1484980. eCollection 2018.

31.

TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves.

Enot DP, Vacchelli E, Jacquelot N, Zitvogel L, Kroemer G.

Oncoimmunology. 2018 Aug 1;7(9):e1462431. doi: 10.1080/2162402X.2018.1462431. eCollection 2018.

32.

Reply to 'Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma'.

Jacquelot N, Zitvogel L, Eggermont AM.

Nat Commun. 2018 Jul 26;9(1):2922. doi: 10.1038/s41467-018-05048-0. No abstract available.

33.

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1.

Derosa L, Routy B, Kroemer G, Zitvogel L.

Oncoimmunology. 2018 Apr 18;7(6):e1434468. doi: 10.1080/2162402X.2018.1434468. eCollection 2018.

34.

Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

García-Martínez E, Smith M, Buqué A, Aranda F, de la Peña FA, Ivars A, Cánovas MS, Conesa MAV, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Feb 15;7(6):e1433982. doi: 10.1080/2162402X.2018.1433982. eCollection 2018. Review.

35.

The gut microbiota influences anticancer immunosurveillance and general health.

Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G.

Nat Rev Clin Oncol. 2018 Jun;15(6):382-396. doi: 10.1038/s41571-018-0006-2. Review.

PMID:
29636538
36.

The impact of the intestinal microbiota in therapeutic responses against cancer.

Goubet AG, Daillère R, Routy B, Derosa L, M Roberti P, Zitvogel L.

C R Biol. 2018 May - Jun;341(5):284-289. doi: 10.1016/j.crvi.2018.03.004. Epub 2018 Apr 7. Review.

37.

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.

Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B.

Ann Oncol. 2018 Jun 1;29(6):1437-1444. doi: 10.1093/annonc/mdy103.

38.

The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies.

Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF.

Science. 2018 Mar 23;359(6382):1366-1370. doi: 10.1126/science.aar6918. Review.

PMID:
29567708
39.

NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis.

Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O.

Immunity. 2018 Feb 20;48(2):396-398. doi: 10.1016/j.immuni.2018.01.010. No abstract available.

40.

Cancer immunotherapy in 2017: The breakthrough of the microbiota.

Kroemer G, Zitvogel L.

Nat Rev Immunol. 2018 Jan 30;18(2):87-88. doi: 10.1038/nri.2018.4. Review. No abstract available.

PMID:
29379189
41.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

42.

eIF2α phosphorylation is pathognomonic for immunogenic cell death.

Bezu L, Sauvat A, Humeau J, Gomes-da-Silva LC, Iribarren K, Forveille S, Garcia P, Zhao L, Liu P, Zitvogel L, Senovilla L, Kepp O, Kroemer G.

Cell Death Differ. 2018 Aug;25(8):1375-1393. doi: 10.1038/s41418-017-0044-9. Epub 2018 Jan 22.

43.

NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis.

Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O.

Immunity. 2018 Jan 16;48(1):107-119.e4. doi: 10.1016/j.immuni.2017.12.007. Epub 2018 Jan 9. Erratum in: Immunity. 2018 Feb 20;48(2):396-398.

44.

Immunogenic and Non-immunogenic Cell Death in the Tumor Microenvironment.

Pitt JM, Kroemer G, Zitvogel L.

Adv Exp Med Biol. 2017;1036:65-79. doi: 10.1007/978-3-319-67577-0_5. Review.

PMID:
29275465
45.

A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.

Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, Degli-Esposti MA, Vivier E, Waddell N, Linden J, Huntington ND, Souza-Fonseca-Guimaraes F, Smyth MJ.

Cancer Res. 2018 Feb 15;78(4):1003-1016. doi: 10.1158/0008-5472.CAN-17-2826. Epub 2017 Dec 11.

46.

Trial watch: DNA-based vaccines for oncological indications.

Pierini S, Perales-Linares R, Uribe-Herranz M, Pol JG, Zitvogel L, Kroemer G, Facciabene A, Galluzzi L.

Oncoimmunology. 2017 Nov 20;6(12):e1398878. doi: 10.1080/2162402X.2017.1398878. eCollection 2017. Review.

47.

Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2017 Oct 4;6(12):e1386829. doi: 10.1080/2162402X.2017.1386829. eCollection 2017. Review.

48.

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Cabo M, Offringa R, Zitvogel L, Kroemer G, Muntasell A, Galluzzi L.

Oncoimmunology. 2017 Aug 30;6(12):e1371896. doi: 10.1080/2162402X.2017.1371896. eCollection 2017. Review.

49.

Trial watch: Immune checkpoint blockers for cancer therapy.

Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J, Spisek R, Demaria S, Formenti SC, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2017 Aug 31;6(11):e1373237. doi: 10.1080/2162402X.2017.1373237. eCollection 2017. Review.

50.

Trial Watch: Adoptively transferred cells for anticancer immunotherapy.

Fournier C, Martin F, Zitvogel L, Kroemer G, Galluzzi L, Apetoh L.

Oncoimmunology. 2017 Aug 11;6(11):e1363139. doi: 10.1080/2162402X.2017.1363139. eCollection 2017. Review.

Supplemental Content

Loading ...
Support Center